Illumina, Inc. and Ovation.io, Inc. announced on May 1, 2025, the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. This dataset will be made available to the pharmaceutical community to advance drug discovery and development.
The collaboration aims to accelerate GLP-1 therapy development, expand indications, and discover novel biomarkers and drug targets, particularly for nonresponsive patient populations. Approximately 40% of Type 2 diabetes patients do not respond effectively to GLP-1 receptor agonists, highlighting the need for deeper molecular understanding.
The initiative leverages Illumina's end-to-end NGS technologies to sequence 25,000 whole genomes and profile protein expression from 5,000 samples using the Illumina Protein Prep (IPP) assay, which detects 9,500 human proteins per sample. This integrated dataset, processed with DRAGEN secondary analysis and Illumina Connected Multiomics, is designed to unlock new insights into GLP-1 response and potential new indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.